European stroke prevention study.
The European Stroke Prevention Study showed: 1. That the association Persantin-Aspirin reduces stroke and vascular death risks with 36,5% in a population of 2500 patients. Risk reduction persisted during the two years follow-up and was the same for men and women. 2. That this reduction is higher than the reduction obtained in all other studies with anti-aggregation prevention. 3. That studies with less than 600 patients cannot lead to significant differences.